<DOC>
	<DOCNO>NCT02008344</DOCNO>
	<brief_summary>The purpose study determine favipiravir effective reducing time resolution influenza symptom .</brief_summary>
	<brief_title>Phase 3 Efficacy Safety Study Favipiravir Treatment Uncomplicated Influenza Adults</brief_title>
	<detailed_description>The purpose study determine 5-day regimen favipiravir reduces time alleviation influenza symptom , resolution fever , viral shedding , subject uncomplicated influenza compare treatment ( e.g . placebo ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>At time enrollment 2 follow symptom ( moderate severe intensity ) begin 48 hour less prior anticipated start dose study medication : cough , sore throat , headache , nasal congestion , body ache pain , fatigue Has fever first visit 6 hour prior antipyretic take , define : ≥ 38.0°C ( ≥ 100.4°F ) &lt; 65 year old ; ≥ 37.8°C ( ≥ 100.0°F ) ≥ 65 year old Tests positive influenza A B 48 hour onset symptom anticipate dose study medication confirm RAT PCR test ( study nonstudy procedure ) ; per Investigator Medical Monitor discretion event know influenza outbreak circulate community subject close contact person recently confirm laboratoryconfirmed influenza Willing adhere strict contraceptive measure throughout study 3 month follow last dose study medication Female subject pregnant , currently breastfeed , positive pregnancy test Screening Has take antiinfluenza drug , receive live attenuate influenza vaccine within 4 week prior sign inform consent Has underlie chronic respiratory disease ; include bronchial asthma currently experience asthma symptom , require current asthma treatment , asthma attack past year Is suspect bacterial respiratory infection ( i.e. , expectoration purulent mucopurulent sputum and/or infiltrate lung observe chest x ray , antibiotic pulmonary disease ) start study Has history gout treatment : gout hyperuricemia ; hereditary xanthinuria ; hypouricemia xanthine calculus urinary tract Has history hypersensitivity antiviral nucleosideanalog drug target viral RNA polymerase Current use adrenocorticosteroids ( except topical preparation ) immunosuppressive drug Has allergy contraindication use acetaminophen ( paracetamol ) Has serious chronic disease , history alcohol drug abuse within precede 2 year , psychiatric illness well control ( stable regimen &gt; 1 year ) , deem Investigator ineligible reason Previously participate clinical trial favipiravir ( T705 ) Has renal insufficiency require hemodialysis continuous ambulatory peritoneal dialysis ( CAPD )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>influenza</keyword>
	<keyword>flu</keyword>
	<keyword>fever</keyword>
	<keyword>cough</keyword>
	<keyword>body ache</keyword>
	<keyword>headache</keyword>
	<keyword>nasal congestion</keyword>
	<keyword>body pain</keyword>
	<keyword>sore throat</keyword>
	<keyword>fatigue</keyword>
	<keyword>T-705</keyword>
	<keyword>favipiravir</keyword>
	<keyword>favor</keyword>
	<keyword>flu symptom</keyword>
</DOC>